Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Liabilities: 2020-2024

Historic Total Liabilities for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $656.5 million.

  • Apellis Pharmaceuticals' Total Liabilities fell 1.08% to $657.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $657.6 million, marking a year-over-year decrease of 1.08%. This contributed to the annual value of $656.5 million for FY2024, which is 10.49% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Total Liabilities of $656.5 million as of FY2024, which was up 10.49% from $594.2 million recorded in FY2023.
  • Apellis Pharmaceuticals' Total Liabilities' 5-year high stood at $756.0 million during FY2020, with a 5-year trough of $590.3 million in FY2022.
  • In the last 3 years, Apellis Pharmaceuticals' Total Liabilities had a median value of $594.2 million in 2023 and averaged $613.7 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Total Liabilities fell by 13.58% in 2022 and then rose by 10.49% in 2024.
  • Apellis Pharmaceuticals' Total Liabilities (Yearly) stood at $756.0 million in 2020, then fell by 9.64% to $683.1 million in 2021, then dropped by 13.58% to $590.3 million in 2022, then increased by 0.65% to $594.2 million in 2023, then climbed by 10.49% to $656.5 million in 2024.